...
首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study
【24h】

Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study

机译:丹麦精神分裂症患者使用抗精神病药的频率和相关性:一项全国性药物流行病学研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Although evidence for efficacy of antipsychotic polypharmacy (APP) is sparse, APP is common in schizophrenia. The national Danish health registers were accessed to examine in schizophrenia patients: (1) cross-sectional prevalences of APP (1996-2012); (2) geographic variations in APP (2012); and (3) correlates of APP (2012). APP increased from 17.2% in 1996 to 30.8% in 2006 (p<0.001), declining to 24.6% in 2012 (p<0.001) (overall trend 1996-2012: alpha=0.653, 95% confidence interval (CI):0.327-0.979, p<0.001). Comparing the 1996-2005 and 2006-2012 cohorts APP occurred significantly faster in the 2006 cohort after schizophrenia diagnosis (p<0.0001). The predominant APP type changed from first-generation antipsychotic combinations in 1996 (77.3%) to first+second-generation antipsychotic combinations in 2003 (70.3%) and second-generation antipsychotic combinations in 2012 (59.2%). In 2012, the prevalence of APP varied from 19.4% in Copenhagen to 29.3% in the region of Zealand. Independent correlates of APP, explaining 37.9% of the variance, included a higher number of patients per psychiatrist (OR= 1.04 /10 patients, CI = 1.03-1.06, p<0.001),lower proportion of males (OR=0.80, Cl =0.74-0.86), younger age (OR= 1.00, Cl =0.99-1.00), several schizophrenia subtypes (paranoid: OR=1.24, CI =1.11-1.38,hebephrenic: OR= 1.30, CI = 1.03-1.63, other: OR= 1.95 CI =1.173.24, unspecified: OR= 1.21 CI =1.05-1.40), living alone (OR=1.12, CI = 1.01-1.24), being institutionalized (OR=1.23, CI = 1.06-1.42), receiving early retirement pension (OR= 1.21, CI=1.10-1.34), higher Charlson Co-morbidity Index score (OR=1.13, CI=1.07-1.19), higher antipsychotic defined daily doses (OR=3.05, Cl= 2.95-3.16), treatment with clozapine (OR=3.09, 95% C1=2.78-3.44), and treatment with antidepressants (OR=1.97 (C1=1.83-2.13), long-acting injectable antipsychotics (OR= 1.48, Cl = 1.34-1.63), and anticholinergics (OR= 1.74, CI = 1.51-2.01). APP remains common in schizophrenia with substantial temporal and geographical variation, being associated with indicators of illness severity and chronicity. (C) 2015 Elsevier By, and ECNP. All rights reserved.
机译:尽管抗精神病药房(APP)疗效的证据很少,但APP在精神分裂症中很常见。访问了丹麦国家卫生注册中心以检查精神分裂症患者:(1)APP横断面患病率(1996-2012); (2)APP(2012)中的地域差异; (3)APP(2012)的相关性。 APP从1996年的17.2%增加到2006年的30.8%(p <0.001),下降到2012年的24.6%(p <0.001)(1996-2012年总体趋势:alpha = 0.653,95%置信区间(CI):0.327- 0.979,p <0.001)。比较1996-2005年和2006-2012年的队列,APP在精神分裂症诊断后的2006年队列发生得更快(p <0.0001)。主要的APP类型从1996年的第一代抗精神病药物组合(77.3%)改变为2003年的第一+第二代抗精神病药物组合(70.3%)和2012年的第二代抗精神病药物组合(59.2%)。 2012年,APP的流行率从哥本哈根的19.4%到西兰地区的29.3%不等。 APP的独立相关性解释了37.9%的差异,其中包括每个精神科医生的患者更多(OR = 1.04 / 10患者,CI = 1.03-1.06,p <0.001),男性比例较低(OR = 0.80,Cl = 0.74-0.86),年龄较小(OR = 1.00,Cl = 0.99-1.00),多种精神分裂症亚型(偏执狂:OR = 1.24,CI = 1.11-1.38,肝肾病:OR = 1.30,CI = 1.3-1.63,其他:OR = 1.95 CI = 1.173.24,未指定:OR = 1.21 CI = 1.05-1.40),独居(OR = 1.12,CI = 1.01-1.24),被寄养(OR = 1.23,CI = 1.06-1.42),早期接受退休金(OR = 1.21,CI = 1.10-1.34),更高的Charlson合并症指数评分(OR = 1.13,CI = 1.07-1.19),较高的抗精神病药定义的日剂量(OR = 3.05,Cl = 2.95-3.16),氯氮平治疗(OR = 3.09,95%C1 = 2.78-3.44),抗抑郁药治疗(OR = 1.97(C1 = 1.83-2.13),长效抗精神病药(OR = 1.48,Cl = 1.34-1.63),和抗胆碱能药(OR = 1.74,CI = 1.51-2.01)。APP在精神分裂症中仍然很常见,并伴有大量te时间和地域差异,与疾病严重程度和慢性病指标相关。 (C)2015 Elsevier By和ECNP。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号